Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Apex Biotechnology Corp. (1733) AI Stock Analysis

TW:1733

Apex Biotechnology Corp.

(TWSE:1733)

Select Model
Rating:61.45Neutral
Price Target:TWD 31.00â–²(8.39% Upside)
Action:initiatedcoverage
Date:11/10/26

The score is primarily supported by a strong, low-leverage balance sheet and attractive valuation. These strengths are substantially offset by sharp revenue contraction, declining cash-flow performance, weaker margins, and bearish technical momentum.

Positive Factors
Conservative balance sheetThe substantial reduction in leverage gives Apex greater financial flexibility and lowers balance-sheet risk over the next several quarters. Sizable equity relative to assets provides a stronger buffer against operating volatility and supports continued investment without relying heavily on additional borrowing.
Negative Factors
Severe revenue contractionThe sharp 2025 revenue contraction materially weakens confidence in near-term earnings durability and indicates that demand or commercial execution has been highly inconsistent. Even with positive margins, a smaller revenue base can reduce operating scale and constrain future cash generation.

Apex Biotechnology Corp. (1733) vs. SPDR S&P 500 ETF (SPY)

-10%-5%0%5%10%15%20%TW:1733-2.92%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 2.87B
Dividend Yield
4.55%
Average Volume (3M)
104.54K
Price to Earnings (P/E)
15.1
Beta (1Y)
0.15
Revenue Growth
-5.22%
EPS Growth
22.94%
Country
TW
Employees
641
Sector
General
Sector Strength
55
Industry
Biotechnology

Apex Biotechnology Corp. Business Overview & Revenue Model

Company Description

Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global development, manufacturing, and distribution of medical devices designed for home use, all powered by sophisticated biosensor technology. Their comprehensive product lineup f...

Apex Biotechnology Corp. Financial Statement Overview

Summary

Strong balance sheet with low leverage, positive profitability, and positive free cash flow support the score. However, severe revenue contraction, weaker margins, and declining operating cash flow indicate inconsistent operating performance.

Income Statement

58Neutral

Balance Sheet

91Very Positive

Cash Flow

61Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.87B1.94B1.85B1.68B2.24B2.13B
Gross Profit567.20M538.74M521.34M531.12M576.84M571.51M
EBITDA226.90M201.65M221.58M221.06M299.07M289.65M
Net Income190.55M163.04M128.00M115.78M181.78M202.22M
Balance Sheet
Total Assets2.55B2.42B2.42B2.30B2.51B2.67B
Cash, Cash Equivalents and Short-Term Investments814.85M644.37M598.78M443.91M397.53M631.25M
Total Debt144.11M148.86M166.16M180.83M243.91M343.28M
Total Liabilities690.93M545.32M595.70M500.07M696.81M916.91M
Stockholders Equity1.86B1.87B1.82B1.80B1.82B1.75B
Cash Flow
Free Cash Flow256.92M148.88M299.04M205.41M-13.58M153.67M
Operating Cash Flow277.65M164.14M328.67M230.39M26.62M179.87M
Investing Cash Flow-12.50M-5.54M-35.60M-22.50M-41.37M-35.02M
Financing Cash Flow-125.64M-132.68M-148.67M-168.14M-237.60M-351.27M

Apex Biotechnology Corp. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:1733 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:1783TW:178376OutperformTWD 3.16B9.38―5.55%8.14%29.10%
TW:1780TW:178071OutperformTWD 2.59B8.03―5.27%――
TW:1733TW:173361NeutralTWD 2.85B15.05―4.55%-5.22%22.94%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:6733TW:673346NeutralTWD 2.80B-31.69――10.74%21.61%
TW:6657TW:665738UnderperformTWD 2.69B-8.88――-4.36%1.97%

* General Sector Average

Performance Comparison

0%50%100%TW:1733TW:1780TW:1783TW:6657TW:6733TW:6934Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:1733 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:1733Apex Biotechnology Corp.28.60-0.81-2.76%
TW:1780Allied Biotech Corp23.703.5917.86%
TW:1783Maxigen Biotech Inc.36.00-6.25-14.80%
TW:6657Energenesis Biomedical Co., Ltd.30.00-11.55-27.80%
TW:6733BioGend Therapeutics Co., Ltd.21.00-17.88-45.98%
TW:6934HCmed Innovations Co., Ltd.73.505.107.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026